Bristol Myers Squibb is considered a better high-yield dividend stock compared to Pfizer, despite Pfizer having a higher forward dividend yield. Bristol Myers Squibb has a stronger track record of dividend growth and sustainability, with a healthier payout ratio, making it a more reliable choice for long-term income-focused investors.
For a knowledgeable investor focused on dividend stocks, the key takeaway is that Bristol Myers Squibb, despite having a lower forward dividend yield than Pfizer, offers stronger dividend growth and sustainability due to its lower payout ratio and better dividend growth track record. This makes Bristol Myers Squibb a potentially more reliable choice for income-focused long-term investors concerned about the durability of their dividend returns.